These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38215191)

  • 1. Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study.
    Suchy-Dicey AM; Longstreth WT; Rhoads K; Umans J; Buchwald D; Grabowski T; Blennow K; Reiman E; Zetterberg H
    Alzheimers Dement; 2024 Mar; 20(3):2072-2079. PubMed ID: 38215191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.
    Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA
    Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment.
    Kivisäkk P; Carlyle BC; Sweeney T; Trombetta BA; LaCasse K; El-Mufti L; Tuncali I; Chibnik LB; Das S; Scherzer CR; Johnson KA; Dickerson BC; Gomez-Isla T; Blacker D; Oakley DH; Frosch MP; Hyman BT; Aghvanyan A; Bathala P; Campbell C; Sigal G; Stengelin M; Arnold SE
    Front Neurol; 2023; 14():1069411. PubMed ID: 36937522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
    Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J
    Alzheimers Res Ther; 2024 Jul; 16(1):165. PubMed ID: 39054505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of plasma amyloid beta
    Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE
    Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.
    Park MK; Ahn J; Kim YJ; Lee JW; Lee JC; Hwang SJ; Kim KC
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
    Chatterjee P; Pedrini S; Ashton NJ; Tegg M; Goozee K; Singh AK; Karikari TK; Simrén J; Vanmechelen E; Armstrong NJ; Hone E; Asih PR; Taddei K; Doré V; Villemagne VL; Sohrabi HR; Zetterberg H; Masters CL; Blennow K; Martins RN
    Alzheimers Dement; 2022 Jun; 18(6):1141-1154. PubMed ID: 34494715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.
    De Meyer S; Blujdea ER; Schaeverbeke J; Reinartz M; Luckett ES; Adamczuk K; Van Laere K; Dupont P; Teunissen CE; Vandenberghe R; Poesen K
    Brain; 2024 Mar; 147(3):936-948. PubMed ID: 37787146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
    Huang Y; Li Y; Xie F; Guo Q
    CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study.
    Zhang Y; Ferreira PCL; Jacobsen E; Bellaver B; Pascoal TA; Snitz BE; Chang CH; Villemagne VL; Ganguli M; Karikari TK
    Alzheimers Dement; 2024 Jun; 20(6):4199-4211. PubMed ID: 38753951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease.
    Yakoub Y; Ashton NJ; Strikwerda-Brown C; Montoliu-Gaya L; Karikari TK; Kac PR; Gonzalez-Ortiz F; Gallego-Rudolf J; Meyer PF; St-Onge F; Schöll M; Soucy JP; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
    Alzheimers Dement; 2023 Dec; 19(12):5620-5631. PubMed ID: 37294682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease.
    Yang Z; Sreenivasan K; Toledano Strom EN; Osse AML; Pasia LG; Cosme CG; Mugosa MRN; Chevalier EL; Ritter A; Miller JB; Cordes D; Cummings JL; Kinney JW
    Alzheimers Res Ther; 2023 Nov; 15(1):190. PubMed ID: 37924152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamics of plasma biomarkers across the Alzheimer's continuum.
    Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
    Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients.
    Gerards M; Schild AK; Meiberth D; Rostamzadeh A; Vehreschild JJ; Wingen-Heimann S; Johannis W; Martino Adami P; Onur OA; Ramirez A; Karikari TK; Ashton NJ; Zetterberg H; Blennow K; Maier F; Jessen F
    Dement Geriatr Cogn Disord; 2022; 51(2):182-192. PubMed ID: 35504263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study.
    Chen Y; Wang Y; Tao Q; Lu P; Meng F; Zhuang L; Qiao S; Zhang Y; Luo B; Liu Y; Peng G
    Clin Chim Acta; 2024 May; 558():118784. PubMed ID: 38588788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real-world population-based cohort.
    Ferreira PCL; Zhang Y; Snitz B; Chang CH; Bellaver B; Jacobsen E; Kamboh MI; Zetterberg H; Blennow K; Pascoal TA; Villemagne VL; Ganguli M; Karikari TK
    Alzheimers Dement; 2023 Oct; 19(10):4507-4519. PubMed ID: 36876954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
    Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
    Rauchmann BS; Schneider-Axmann T; Perneczky R;
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study.
    Dong Y; Hou T; Li Y; Liu R; Cong L; Liu K; Liu C; Han X; Ren Y; Tang S; Winblad B; Blennow K; Wang Y; Du Y; Qiu C
    J Alzheimers Dis; 2023; 96(2):845-858. PubMed ID: 37899059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.